Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
InnoCan Pharma: Multi-Milliarden-Wert in diesem Pennystock?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
138 Leser
Artikel bewerten:
(0)

China Biologic Products Schedules Conference Call to Discuss Second Quarter 2010 Results

TAI'AN, China, Aug. 12 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that it will host a conference call at 8:00 a.m. Eastern Daylight Time on Monday, August 16, 2010, to discuss its second quarter 2010 results.

Hosting the call will be Mr. Colin Zhao, its Chief Executive Officer, and Mr. Tristan Kuo, its Chief Financial Officer. The Company plans to distribute its earnings press release prior to the call.

To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 877-409-5468. International callers should dial +1-702-894-2400. Please refer to conference ID 94191315.

If you are unable to participate in the call at this time, a replay will be available for 14 days starting on Monday, August 16, 2010 at 9:00 a.m. EDT. To access the replay, dial 800-642-1687, international callers should dial +1-706-645-9291, and enter conference ID 94191315.

About China Biologic Products, Inc.

China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China. Please see the Company's website http://www.chinabiologic.com/ for additional information.

For more information, please contact: Company Contact: Mr. Y. Tristan Kuo Chief Financial Officer China Biologic Products, Inc. Tel: +86-538-6202206 Email: IR@chinabiologic.com Web: http://www.chinabiologic.com/ Investor Relations Contact: Ms. Kalle Ahl, Account Manager CCG Investor Relations Phone: +1-646-833-3417 Email: kalle.ahl@ccgir.com Web: http://www.ccgirasia.com/ Mr. Crocker Coulson, President Phone: +1-646-213-1915 Email: crocker.coulson@ccgir.com

China Biologic Products, Inc.

CONTACT: Company Contact: Mr. Y. Tristan Kuo, Chief Financial Officer,
China Biologic Products, Inc. at +86-538-6202206 or IR@chinabiologic.com;
Investor Relations Contact: Mr. Kalle Ahl, Account Manager, CCG Investor
Relations at +1-646-833-3417 or kalle.ahl@ccgir.com; Mr. Crocker Coulson,
President, CCG Investor Relations at +1-646-213-1915 or
crocker.coulson@ccgir.com

Web site: http://www.chinabiologic.com/
http://www.ccgirasia.com/

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2010 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.